Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The January 2017 monograph topics are bezlotoxumab, buprenorphine buccal, defazacort, dupilumab, and olaratumab. The DUE is on buprenorphine buccal.
Get full access to this article
View all access options for this article.
References
1.
Adlyxin (lixisenatide) [prescribing information].Bridgewater, NJ: Sanofi-Aventis; July 2016.
BolliG.B., MunteanuM., DotsenkoS.Efficacy and safety of lixisenatide once daily vs placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med.2014; 31(2): 176–184.
4.
CharbonnelB., BertoliniM., TinahonesF.J., DomingoM.P., DaviesM.Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: A meta-analysis. J Diabetes Complications.2014; 28(6): 880–886.
5.
FonsecaV.A., Alvarado-RuizR., RaccahD., BokaG., MiossecP., GerichJ.E.Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care.2012; 35(6): 1225–1231.
6.
PingetM., GoldenbergR., NiemoellerE., Meuhlen-BartmerI., GuoH., AronsonR.Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metabol.2013; 15(11): 1000–1007.
7.
RiddleM.C., AronsonR., HomeP.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care.2013; 36(9): 2489–2496.
8.
RiddleM.C., ForstT., AronsonR.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: A 24-week, randomized, placebo-controlled comparison (GetGoal-Duo 1). Diabetes Care.2013; 36(9): 2497–2503.
9.
RosenstockJ., RaccahD., KorányiL.Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care.2013; 36(10): 2945–2951.
10.
SeinoY., MinK.W., NiemoellerE., TakamiA.; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metabol.2012; 14(10): 910–917.
11.
Van GaalL., SouhamiE., ZhouT., AronsonR.Efficacy and safety of glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus. J Clin Trans Endocrinol.2014; 1(2): 31–37.
12.
Yu PanC., HanP., LiuX.Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: A randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metabol Res Rev.2014; 30(8): 726–735.
13.
Bydureon (exenatide) [prescribing information].Wilmington, DE: AstraZeneca Pharmaceuticals; September 2015.
14.
Byetta (exenatide) [prescribing information].Wilmington, DE: AstraZeneca Pharmaceuticals; February 2015.
15.
Tanzeum (albiglutide) [prescribing information].Research Triangle Park, NC: GlaxoSmithKline; July 2015.
16.
Trulicity (dulaglutide) [prescribing information].Indianapolis, IN: Eli Lilly and Company; July 2015.
17.
Victoza (liraglutide) [prescribing information].Princeton, NJ: Novo Nordisk Inc; April 2016.
18.
WernerU., HaschkeG., HerlingA.W., KramerW.Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept.2010; 164(2-3): 58–64.
19.
WilkinsJ.J., DubarM., SébastienB., LaveilleC.A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes. J Clin Pharmacol.2014; 54(3): 267–278.
20.
ArodaV.R., RatnerR.The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: A review. Diabetes Metabol Res Rev.2011; 27(6): 528–542.
21.
BarnettA.H.Lixisenatide: Evidence for its potential use in the treatment of type 2 diabetes. Core Evid.2011; 6: 67–79.
22.
BeckerR.H., StechlJ., MsihidJ., KapitzaC.Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes–a study in both people with type 2 diabetes and healthy subjects. Diabetes Obes Metabol.2014; 16(9): 793–800.
23.
BeckerR.H., StechlJ., SteinstraesserA., GolorG., PellissierF.Lixisenatide reduces postprandial hyperglycaemia via gastro-static and insulinotropic effects. Diabetes Metabol Res Rev.2015; 31(6): 610–618.
24.
LorenzM., PfeifferC., SteinstraberA., RuusP.Effects of lixisenatide once daily on gastric emptying and relationship to postprandial glycemia in type 2 diabetes mellitus [abstract]. 72nd Annual Scientific Sessions of the American Diabetes Association; June 8–12, 2012; Philadelphia, PA. Abstract 1085-P.
25.
NockV., RuppelD., KloftC.Comparison of three PK/PD models for glycated haemoglobin in diabetes type 2 patients treated with lixisenatide [abstract]. 2012 Annual Meeting of Population Approach Group in Europe; June 5–8, 2012; Venice, Italy. Abstract 2335.
26.
WernerU., Kuhlmann-GottkeJ., SchferH.L., HerlingA.W.Effect of the once-daily GLP-1R agonist lixisenatide on gastric emptying and prandial carbohydrate utilization in animal models: A comparison with liraglutide [abstract]. 71st Annual Scientific Sessions of the American Diabetes Association; June 24–28, 2011; San Diego, CA. Abstract 2267-PO.
27.
WernerU., GerlachM., HofmannM., HerlingA.W.Combination of lixisenatide and insulin glargine demonstrates complementary pharmacological activity on glycemic control in animal models of diabetes [abstract]. 72nd Annual Scientific Sessions of the American Diabetes Association; June 8–12, 2012; Philadelphia, PA. Abstract 1051-P.
28.
RaccahE., MiossecP., EspositoV., NiemoellerE., ChoM., GerichJ.E.Efficacy and safety of lixisenatide in elderly (> 65 yr) patients with type 2 diabetes: An analysis from the GetGoal Phase 3 Program [abstract]. 72nd Annual Scientific Sessions of the American Diabetes Association; June 8–12, 2012; Philadelphia, PA. Abstract 972-P.
29.
RatnerR.E., RosenstockJ., BokaG.; DRI6012 Study Investigators. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled trial. Diabet Med.2010; 27(9): 1024–1032.
30.
RosenstockJ., HanefeldM., ShamannaP.Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complications.2014; 28(3): 386–392.
GarberA.J., AbrahamsonM.J., BarzilayJ.I.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm — 2016 executive summary. Endocr Pract.2016; 22(1): 84–113.
NauckM., RizzoM., JohnsonA., Bosch-TrabergH., MadsenJ., CariouB.Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: A 26-week randomized controlled clinical trial. Diabetes Care.2016; 39(9): 1501–1509.
35.
PfefferM.A., ClaggettB., DiazR.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med.2015; 373(23): 2247–2257.
36.
LiuY.H., RussP., SteinstraesserA., TeichertL.Effect of the GLP-1 agonist lixisenatide on the pharmacokinetics of warfarin [abstract]. 70th Annual Scientific Sessions of the American Diabetes Association; June 25–29, 2010; Orlando, FL. Abstract 2128-PO.
37.
AhrénB., VorokhobinaN., SouhamiE., DemilN., YeJ., AronsonR.Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day. J Diabetes Complications.2014; 28(5): 735–741.
38.
AhrénB., Leguizamo DimasA., MiossecP., SaubaduS., AronsonR.Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care.2013; 36(9): 2543–2550.
